mRNA-1273, BNT162b2 Vaccines Comparable for Lowering COVID-19 Risk

mRNA-1273 marginally more effective than BNT162b2 among U.S. veterans, but risk for outcomes at 24 weeks low with both vaccines

vial vaccine syringe
Adobe Stock

THURSDAY, Dec. 2, 2021 (HealthDay News) -- The 24-week risk for COVID-19 outcomes is slightly lower after vaccination with mRNA-1273 than BNT162b2, according to a study published online Dec. 1 in the New England Journal of Medicine.

Barbra A. Dickerman, Ph.D., from CAUSALab in Boston, and colleagues emulated a target trial using the electronic health records of U.S. veterans who received a first dose of BNT162b2 or mRNA-1273 vaccine between Jan. 4 and May 14, 2021, which was marked by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.7 (alpha) variant predominance. A second target trial involving veterans vaccinated between July 1 and Sept. 20, 2021, was emulated to assess the influence of the B.1.617.2 (delta) variant.

A total of 219,842 participants were included in each vaccine group. The researchers found that the estimated risk for documented infection was 5.75 (95 percent confidence interval [CI], 5.39 to 6.23) and 4.52 (95 percent CI, 4.17 to 4.84) events per 1,000 persons in the BNT162b2 and mRNA-1273 groups, respectively, during 24 weeks of follow-up in a period marked by alpha variant predominance. For BNT162b2 versus mRNA-1273, the excess number of events per 1,000 persons was 1.23 (95 percent CI, 0.72 to 1.81) for documented infection, 0.44 (95 percent CI, 0.25 to 0.70) for symptomatic COVID-19, 0.55 (95 percent CI, 0.36 to 0.83) for COVID-19 hospitalization, 0.10 (95 percent CI, 0.00 to 0.26) for intensive care unit admission for COVID-19, and 0.02 (95 percent CI, −0.06 to 0.12) for death from COVID-19. For documented infection over 12 weeks during delta variant predominance, the corresponding excess risk for BNT162b2 versus mRNA-1273 was 6.54 events per 1,000 persons (95 percent CI, −2.58 to 11.82).

"Although when we look at hundreds of thousands of recipients, mRNA-1273 is marginally more effective than BNT162b2, the death rate among vaccinated persons remains tiny," write the authors of an accompanying editorial.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Physician's Briefing